港股创新药板块回调引资金逆势“抢筹”，恒生创新药ETF（159316）今日净申购近1亿份

Group 1 - The Hong Kong innovative drug sector experienced a pullback after four consecutive days of gains, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index down by 2.2% as of 14:57 [1] - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume of 700 million yuan, with a net subscription of nearly 100 million shares, indicating significant growth with over 500 million yuan net inflow in the past month [1] - The 18th Western Pacific Conference, dubbed the "Davos of the Health Industry," recently opened in Boao, focusing on drug research and development, payment innovation, and outpatient services, highlighting the new value in the pharmaceutical industry [1] Group 2 - Experts at the conference believe that China's innovative drug industry is poised for a new growth wave, driven by advantages in the entire chain of innovation, accelerated internationalization, and continuous policy support [1] - The recent revision of the Hang Seng Hong Kong Stock Connect Innovative Drug Index has officially excluded CXO companies, making it the first index with a 100% "purity" in tracking innovative drugs [1] - Backtesting data shows that the adjusted index has higher annualized returns and Sharpe ratios since its launch on July 10, 2023, making the Hang Seng Innovative Drug ETF (159316) the only product tracking this index, providing investors with precise opportunities in the innovative drug sector [1]